Incyte Corporation cash flow to debt ratio of 2.04K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Incyte Corporation's free cash flow has increased 443.87% from $249.07M last year to $1.35G, signaling increasing performance

Incyte Corporation's debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Incyte Corporation's debt has decreased relative to shareholder equity from 0.01 last year to 0.01 today, signaling strengthened financials

Incyte Corporation has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Incyte Corporation earns at least as much interest as it pays. Interest obligations are fully covered.

Incyte Corporation's profit margin has increased (3.37K%) in the last year from 0.77% to 26.71%, signaling increasing performance

Incyte Corporation's short-term assets of $5.02G exceed its short-term liabilities of $1.52G

Incyte Corporation's return on assets of 19.51% is higher than the 5.00% threshold, indicating efficient asset utilization

Incyte Corporation's return on equity of 29.31%, is higher than 15.00%, indicating good performance

Incyte Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Incyte Corporation had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Incyte Corporation has positive free cash flow, indicating the company generates cash after capital expenditures

Incyte Corporation has a free cash flow yield of 5.96%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Incyte Corporation's yearly earnings has increased 3.84K% since last year from $32.62M to $1.29G, signaling increasing performance

Incyte Corporation's yearly revenue has increased 21.22% since last year from $4.24G to $5.14G, signaling increasing performance

ROIC 20.13% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Incyte Corporation's 3-year revenue CAGR of 14.84% is positive, indicating growing revenue over the past 3 years

Incyte Corporation had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Incyte Corporation had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Incyte Corporation has insufficient data to evaluate this check.

Incyte Corporation has an earnings yield of 6.31%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Incyte Corporation is overvalued relative to its fair value price of 77.13 based on EBITDA multiple model

Incyte Corporation has an EV/EBITDA ratio of 10.31x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Incyte Corporation is overvalued relative to its fair value price of 75.84 based on Earnings Fair Value model

Incyte Corporation has a PEG-ratio under 1 which is considered undervalued

Incyte Corporation has a price-to-book ratio of 4.08x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Incyte Corporation has a price-to-sales ratio of 4.24x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue